"EC approves GSK’s RSV vaccine for adults aged 50-59 years" was originally created and published by Pharmaceutical Technology ...

AREXVY is approved for the prevention of lower respiratory ... Indication for SHINGRIX SHINGRIX is an FDA-approved vaccine for the prevention of shingles (herpes zoster) in: Adults 50 years and older.

GSK (NYSE:GSK) announced Wednesday that its Arexvy vaccine for respiratory syncytial virus (RSV) and its Shingrix vaccine for ...

Since an initial FDA go-ahead in 2020, Sanofi’s Sarclisa has been specifically approved for patients with previously treated ...

Zevra Therapeutics Inc. (ZVRA) made headlines yesterday with a landmark FDA approval for its innovative drug, MIPLYFFA, in the ...

Moderna pushed back its break-even goal by two years on Thursday as it delayed the timeline for developing several key ...

Sanofi said the Food and Drug Administration has approved Sarclisa as a first line combined treatment option for adult patients with newly diagnosed multiple myeloma who aren't eligible for autologous ...

GSK released data from a Phase 3 trial evaluating the co-administration of Arexvy and Shingrix vaccines in adults 50+. The ...

The U.S. Food and Drug Administration said on Friday it has approved AstraZeneca's nasal spray flu vaccine for ...

The FDA says the latest vaccine formulae "closely targets currently circulating variants" to give better protection against ...

If approved, the co-administration of Arexvy and Shingrix could provide a more convenient vaccination regimen for patients ...

The Food and Drug Administration announced Friday it had broadened the approval of the FluMist nasal spray to become the ...